EP
AVEO

Eudaimonia Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Eudaimonia Partners’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,624
Closed -$48K – 1531
2021
Q1 		$48K Buy
+6,624
New +$57.1K 0.01% 652

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Eudaimonia Partners's AVEO Position: Q2 2021 in Review

Eudaimonia Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2021, closing a stake of 6,624 shares — an estimated $48K sold.

Eudaimonia Partners first reported a position in AVEO in Q1 2021 and held it in 1 quarter. The position peaked at $48K in Q1 2021. 63 funds tracked by Wall St. Rank hold AVEO as of Q2 2021.

  • Eudaimonia Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 6,624 AVEO Pharmaceuticals, Inc. shares in Q2 2021, an estimated $48K.
  • Eudaimonia Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's AVEO Pharmaceuticals, Inc. position peaked at $48K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.